Immunomodulator toxicity in connective tissue disorders surfaced as a measurable bedside problem
Immunomodulators remain central to the treatment of connective tissue disorders, yet the same drugs that control inflammation can also create a second layer of risk for patients who need long-term therapy. In a hospital-based cross-sectional study at AIIMS Nagpur, 105 adults with connective tissue disorders receiving immunomodulators for more than one month were assessed for adverse drug reactions, and 19 ADRs were identified across the cohort. The pattern that emerged was not one of catastrophic toxicity, but of repeated, clinically relevant harm that can interrupt treatment if it is missed or normalized.
The median clinical picture was shaped by commonly used agents rather than rare outliers. Prednisolone, methotrexate, and hydroxychloroquine were the drugs most often implicated, and the reactions spanned central serous retinopathy, hypertension, oral ulcers, and rashes. Each of those events has direct treatment consequences. Steroid-related blood pressure elevation can quietly accumulate over time; methotrexate-associated mucosal ulceration can affect nutrition and adherence; hydroxychloroquine-related ocular toxicity demands vigilance because visual symptoms may appear after injury has already begun. In connective tissue disorders, the clinical challenge is not only suppressing disease activity, but doing so without eroding the very functional gains therapy is meant to deliver.
Causality tools pointed to drug-related injury rather than background noise
The investigators applied standard pharmacovigilance frameworks, including the WHO-UMC system, the Naranjo algorithm, the Hartwig-Siegel severity scale, and the Schumock-Thornton preventability scale. Across those assessments, the majority of events clustered in categories that support a real medication relationship instead of incidental coincidence. By WHO-UMC criteria, 71.4% of reactions were judged probable, while the Naranjo scale classified 57.9% as probable. Those findings matter because connective tissue disorders often involve complex symptom burdens, and without structured causality review, a rash, ulcer, or blood pressure rise can be incorrectly dismissed as part of the underlying disease process.
The severity distribution stayed mostly in the mild-to-moderate range, accounting for 89.5% of ADRs. No life-threatening outcomes occurred. This is reassuring, but it should not lead to complacency. Mild and moderate adverse effects are often the ones that silently drive nonadherence, dose reduction, or self-discontinuation, especially when the side effect seems routine to the patient and therefore never reaches the clinician’s attention.
Preventability stood out as the most actionable signal
A striking 84.2% of the reactions were considered probably preventable. In practical terms, this points toward missed opportunities in counseling, anticipatory monitoring, or dose adjustment rather than unavoidable toxicity alone. When a patient develops oral ulcers on methotrexate, or hypertension after corticosteroid exposure, the harm is not merely pharmacologic; it is also operational. It reflects how well the clinic has translated drug monitoring into everyday care.
That preventability signal is especially important in connective tissue disorders because treatment often stretches over months or years. Over time, small toxicities can compound into real disease-management failures. A patient with central serous retinopathy may need immediate ophthalmologic attention. A patient with recurrent mucosal ulcers may stop methotrexate on their own. A patient with steroid-induced hypertension may require treatment changes that were not anticipated at the outset. The data from this cohort suggest that many of these problems can be reduced before they become reasons for abandonment of therapy.
Demographic factors did not explain who developed reactions
No significant associations were found between ADR occurrence and sex, age group, or comorbidity status, with all P values greater than 0.05. The cohort was predominantly female, with women making up 76.2% of the 105 participants, and the mean age was 42.68 ± 15.55 years. Even so, the occurrence of adverse reactions did not track cleanly with those baseline characteristics. In other words, the risk signal was distributed across the population rather than concentrated in a single easily identifiable subgroup.
This matters at the bedside because it argues against relying on demographic shortcuts when monitoring treatment tolerance. The absence of a statistically significant association does not erase clinical vigilance in older adults, younger adults, or those with comorbidity; it simply says that any patient receiving these agents can develop toxicity, and routine surveillance remains necessary regardless of the patient’s age or sex.
Routine monitoring should be built into immunomodulator care
The study supports a straightforward clinical interpretation: immunomodulator-related ADRs in connective tissue disorders are usually detectable, usually not severe, and often avoidable if monitoring is consistent. That conclusion fits the pharmacology of the drugs involved. Corticosteroids can drive metabolic and vascular complications. Methotrexate can affect mucosal integrity and tolerability. Hydroxychloroquine requires attention to ocular safety. When these agents are used together or sequentially in chronic inflammatory disease, the probability of cumulative treatment burden rises even if each individual event seems modest.
A practical monitoring culture therefore becomes part of therapy, not an optional add-on. Patients need clear counseling about symptoms that should trigger review, including new visual changes, persistent mouth ulcers, skin eruptions, and blood pressure elevation. Clinicians need a low threshold to review concomitant medications, dose schedules, and the timing of symptom onset. Pharmacovigilance systems work best when they are close to the prescription pad rather than distant from it.
The study’s limitations are built into its design: it was cross-sectional, conducted at a single center, and captured ADR patterns over a six-month period. Even with those constraints, the findings offer a clean clinical message for patients with connective tissue disorders receiving immunomodulators. Most reactions were probable, mild-to-moderate, and largely preventable, which makes structured follow-up the most immediate defense against avoidable harm.